Recombinant Human TGF-β sRII
Transforming growth factor beta type II (TGFbeta RII) is a disulfide-linked homodimer and is a key inhibitor of epithelial cell growth and tumor suppressor gene.1 It also regulate cell differentiation and has critical regulatory roles in the process of tissue repair and remodeling.2 TGF beta RII plays an important role as a tumor suppressor in non-small cell lung cancer (NSCLC) carcinogenesis.1 TGF can be found in many different tissue types, including brain, heart, kidney, liver and testes. Over-expression of TGF can induce renal fibrosis, causing kidney disease, as well as diabetes, and ultimately end-stage renal disease (ESRD). Recent developments have found that, using certain types of protein antagonists against TGFβ receptors, can halt and in some cases reverse the effects of renal fibrosis. Three TGF-β receptor types can be distinguished by their structural and functional properties. Receptor types I and II have similar ligand binding affinities and can only be distinguished from each other by peptide mapping, both receptor types I and II have a high affinity for TGF-β1 and low affinity for TGF-β2. TGF-β receptor type III has a high affinity for both TGF-β1 and -β2.
>97% by SDS Page and analyzed by silver stain.
<0.1 EU/µg as determined by the LAL method
The biological activity of Human TGF-β sRII was determined by its ability to inhibit TGF-β1 activity on a mouse T cell line, HT2. The expected ED<sub>50</sub> for this effect is typically 10 - 40 ng/mL in the presence of 1 ng/mL of rhTGF-β1.
Protein Accession No.
Amino Acid Sequence
tipphvqksv nndmivtdnn gavkfpqlck fcdvrfstcd nqkscmsncs itsicekpqe vcvavwrknd enitletvch dpklpyhdfi ledaaspkci mkekkkpget ffmcscssde cndniifsee yntsnpdmdp kscdkthtcp pcpapellgg psvflfppkp kdtlmisrtp evtcvvvdvs hedpevkfnw yvdgvevhna ktkpreeqyn styrvvsvlt vlhqdwlngk eykckvsnka lpapiektis kakgqprepq vytlppsrde ltknqvsltc lvkgfypsdi avewesngqp ennykttppv ldsdgsffly skltvdksrw qqgnvfscsv mhealhnhyt qkslslspgk
N-terminal Sequence Analysis
State of Matter
Predicted Molecular Mass
The predicted molecular weight of Recombinant Human TGF-β sRII is Mr 41.7 kDa. However, the actual molecular weight as observed by migration on SDS-PAGE is 59-66 kDa (reducing conditions).
Predicted Molecular Mass
This recombinant protein was 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 with no calcium, magnesium, or preservatives.
Storage and Stability
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Country of Origin
Next Day Ambient
NCBI Gene Bank
References & Citations
1. Luo, Z. et al. (2004) Clin Cancer Res. 10: 2359
2. Longaker, MT. et al. (1997) Am J Pathol. 150: 209
IMPORTANT Use lot specific datasheet for all technical information pertaining to this recombinant protein.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.